Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 230

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Molecular biomarkers of Alzheimer's disease: progress and prospects

Open access
Lashley, Tammaryn, Schott, Jonathan M., Weston, Philip, Murray, Christina E., Wellington, Henny, Keshavan, Ashvini, Foti, Sandrine C., Foiani, Martha, Toombs, Jamie, Rohrer, Jonathan D., Heslegrave, Amanda, Zetterberg, Henrik · 2018 · Disease Models & Mechanisms

Abstract

The neurodegenerative disorder Alzheimer's disease is characterised by the formation of β-amyloid plaques and neurofibrillary tangles in the brain parenchyma, which cause synapse and neuronal loss. This leads to clinical symptoms, such as progressive memory deficits. Clinically, these pathological changes can be detected in the cerebrospinal fluid and with brain imaging, although reliable blood tests for plaque and tangle pathologies remain to be developed. Plaques and tangles often co-exist with other brain pathologies, including aggregates of transactive response DNA-binding protein 43 and Lewy bodies, but the extent to which these contribute to the severity of Alzheimer's disease is currently unknown. In this ‘At a glance’ article and poster, we summarise the molecular biomarkers that are being developed to detect Alzheimer's disease and its related pathologies. We also highlight the biomarkers that are currently in clinical use and include a critical appraisal of the challenges associated with applying these biomarkers for diagnostic and prognostic purposes of Alzheimer's disease and related neurodegenerative disorders, also in their prodromal clinical phases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1242/dmm.031781

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 66

  1. Abdelnour, 2016, Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia, Mov. Disord., 31, 1203, 10.1002/mds.26668 · DOI
  2. Andreasson, 2016, Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders, Alzheimers Dement., 3, 98, 10.1016/j.dadm.2016.05.005 · DOI
  3. Barbour, 2008, Red blood cells are the major source of alpha-synuclein in blood, Neurodegener. Dis., 5, 55, 10.1159/000112832 · DOI · Paper page
  4. Blennow, 2006, Alzheimer's disease, Lancet, 368, 387, 10.1016/S0140-6736(06)69113-7 · DOI · Paper page
  5. Brinkmalm, 2014, SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease, Mol. Neurodegener., 9, 53, 10.1186/1750-1326-9-53 · DOI · Paper page
  6. Burnham, 2016, Predicting Alzheimer disease from a blood-based biomarker profile: a 54-month follow-up, Neurology, 87, 1093, 10.1212/WNL.0000000000003094 · DOI
  7. Chhatwal, 2016, Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly, Neurology, 87, 920, 10.1212/WNL.0000000000003050 · DOI · Paper page
  8. Corrêa, 2011, Chemokines in CSF of Alzheimer's disease patients, Arq. Neuropsiquiatr., 69, 455, 10.1590/S0004-282X2011000400009 · DOI
  9. De Vos, 2015, C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease, Alzheimers Dement., 11, 1461, 10.1016/j.jalz.2015.05.012 · DOI
  10. Feneberg, 2014, Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases, Amyotroph. Lateral Scler. Frontotemporal. Degener., 15, 351, 10.3109/21678421.2014.905606 · DOI
  11. Fodero-Tavoletti, 2009, In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies, Eur. J. Pharmacol., 617, 54, 10.1016/j.ejphar.2009.06.042 · DOI
  12. Galimberti, 2006, Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration, Neurology, 66, 146, 10.1212/01.wnl.0000191324.08289.9d · DOI
  13. Hall, 2012, Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders, Arch. Neurol., 69, 1445, 10.1001/archneurol.2012.1654 · DOI · Paper page
  14. Hansson, 2014, Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease, Alzheimers Res. Ther., 6, 25, 10.1186/alzrt255 · DOI · Paper page
  15. Hellwig, 2015, Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease, Alzheimers Res. Ther., 7, 74, 10.1186/s13195-015-0161-y · DOI
  16. Hesse, 2001, Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke, Neurosci. Lett., 297, 187, 10.1016/S0304-3940(00)01697-9 · DOI · Paper page
  17. Jack, 2013, Biomarker modeling of Alzheimer's disease, Neuron, 80, 1347, 10.1016/j.neuron.2013.12.003 · DOI · Paper page
  18. James, 2016, TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia, Brain, 139, 2983, 10.1093/brain/aww224 · DOI · Paper page
  19. Kaneko, 2014, Novel plasma biomarker surrogating cerebral amyloid deposition, Proc. Jpn. Acad. Ser. B Phys. Biol. Sci., 90, 353, 10.2183/pjab.90.353 · DOI
  20. Kapaki, 2013, The diagnostic value of CSF alpha-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease, PLoS ONE, 8, e81654, 10.1371/journal.pone.0081654 · DOI
  21. Kester, 2015, Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease, JAMA Neurol., 72, 1275, 10.1001/jamaneurol.2015.1867 · DOI · Paper page
  22. Kikuchi, 2010, In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy, Brain, 133, 1772, 10.1093/brain/awq091 · DOI
  23. Klunk, 2004, Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B, Ann. Neurol., 55, 306, 10.1002/ana.20009 · DOI · Paper page
  24. Kolb, 2017, Tau positron emission tomography imaging, Cold Spring Harb. Perspect. Biol., 9, a023721, 10.1101/cshperspect.a023721 · DOI
  25. Kovacs, 2016, Molecular pathological classification of neurodegenerative diseases: turning towards precision medicine, Int. J. Mol. Sci., 17, 189, 10.3390/ijms17020189 · DOI · Paper page
  26. Kuhlmann, 2016, CSF Abeta1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation, Clin. Chim. Acta, 467, 27, 10.1016/j.cca.2016.05.014 · DOI
  27. Kvartsberg, 2015, Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease, Alzheimers Dement., 11, 1180, 10.1016/j.jalz.2014.10.009 · DOI · Paper page
  28. Kvartsberg, 2015, Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls, Alzheimers Res. Ther., 7, 40, 10.1186/s13195-015-0124-3 · DOI
  29. Lagarde, 2017, In vivo PET imaging of neuroinflammation in Alzheimer's disease, J. Neural. Transm. (Vienna), 125, 847, 10.1007/s00702-017-1731-x · DOI
  30. Lashley, 2008, Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients, Acta Neuropathol., 115, 417, 10.1007/s00401-007-0336-0 · DOI · Paper page
  31. Magdalinou, 2015, A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes, J. Neurol. Neurosurg. Psychiatry, 86, 1240, 10.1136/jnnp-2014-309562 · DOI · Paper page
  32. Marquié, 2015, Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue, Ann. Neurol., 78, 787, 10.1002/ana.24517 · DOI · Paper page
  33. Mattsson, 2016, Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease, J. Neurol. Neurosurg. Psychiatry, 87, 1000, 10.1136/jnnp-2015-311321 · DOI
  34. Mattsson, 2017, (18)F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease, EMBO Mol. Med., 9, 1212, 10.15252/emmm.201707809 · DOI · Paper page
  35. Mollenhauer, 2010, Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies, Biomark. Med., 4, 683, 10.2217/bmm.10.90 · DOI
  36. Mollenhauer, 2011, alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study, Lancet Neurol., 10, 230, 10.1016/S1474-4422(11)70014-X · DOI · Paper page
  37. Morbelli, 2018, Amyloid PET imaging: standardization and integration with other Alzheimer's disease biomarkers, Methods Mol. Biol., 1750, 203, 10.1007/978-1-4939-7704-8_13 · DOI
  38. Oeckl, 2016, Alpha-, Beta-, and gamma-synuclein quantification in cerebrospinal fluid by multiple reaction monitoring reveals increased concentrations in Alzheimer's and Creutzfeldt-Jakob disease but no alteration in synucleinopathies, Mol. Cell. Proteomics, 15, 3126, 10.1074/mcp.M116.059915 · DOI
  39. Öhrfelt, 2009, Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?, Neurosci. Lett., 450, 332, 10.1016/j.neulet.2008.11.015 · DOI · Paper page
  40. Öhrfelt, 2016, Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone, Mult. Scler., 22, 1587, 10.1177/1352458515624558 · DOI
  41. Olsson, 2013, Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia, J. Alzheimers Dis., 33, 45, 10.3233/JAD-2012-120787 · DOI
  42. Olsson, 2016, CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis, Lancet Neurol., 15, 673, 10.1016/S1474-4422(16)00070-3 · DOI · Paper page
  43. Payoux, 2017, New PET markers for the diagnosis of dementia, Curr. Opin. Neurol., 30, 606, 10.1097/WCO.0000000000000489 · DOI
  44. Peluso, 2017, Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection, AIDS, 31, 247, 10.1097/QAD.0000000000001314 · DOI
  45. Portelius, 2015, Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease, Brain, 138, 3373, 10.1093/brain/awv267 · DOI · Paper page
  46. Ramont, 2005, Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice, Clin. Chem. Lab. Med., 43, 1215, 10.1515/CCLM.2005.210 · DOI · Paper page
  47. Represa, 1990, Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate, J. Neurosci., 10, 3782, 10.1523/JNEUROSCI.10-12-03782.1990 · DOI · Paper page
  48. Schmidt, 2015, The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data, Alzheimers Dement., 11, 1050, 10.1016/j.jalz.2014.09.004 · DOI
  49. Schneider, 2009, The neuropathology of probable Alzheimer disease and mild cognitive impairment, Ann. Neurol., 66, 200, 10.1002/ana.21706 · DOI · Paper page
  50. Schott, 2012, Alzheimer's disease: mimics and chameleons, Pract. Neurol., 12, 358, 10.1136/practneurol-2012-000315 · DOI
  51. Shahnawaz, 2016, Development of a biochemical diagnosis of Parkinson disease by detection of alpha-Synuclein misfolded aggregates in cerebrospinal fluid, JAMA Neurol., 74, 163, 10.1001/jamaneurol.2016.4547 · DOI · Paper page
  52. Simonsen, 2017, Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia, Alzheimers Dement., 13, 274, 10.1016/j.jalz.2016.09.008 · DOI · Paper page
  53. Smailagic, 2015, (1)(8)F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI), Cochrane Database Syst. Rev., 1, CD010632, 10.1002/14651858.CD010632.pub2 · DOI · Paper page
  54. Steinacker, 2016, Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease, Sci. Rep., 6, 38737, 10.1038/srep38737 · DOI
  55. Tarawneh, 2016, Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease, JAMA Neurol., 73, 561, 10.1001/jamaneurol.2016.0086 · DOI · Paper page
  56. Tokuda, 2010, Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease, Neurology, 75, 1766, 10.1212/WNL.0b013e3181fd613b · DOI · Paper page
  57. van Eijk, 2010, CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt-Jakob disease, J. Alzheimers Dis., 21, 569, 10.3233/JAD-2010-090649 · DOI
  58. Voyle, 2015, Blood protein markers of neocortical amyloid-beta burden: a candidate study using SOMAscan technology, J. Alzheimers Dis., 46, 947, 10.3233/JAD-150020 · DOI
  59. Wallin, 2010, CSF biomarkers predict a more malignant outcome in Alzheimer disease, Neurology, 74, 1531, 10.1212/WNL.0b013e3181dd4dd8 · DOI · Paper page
  60. Watabe-Rudolph, 2012, Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease, Neurology, 78, 569, 10.1212/WNL.0b013e318247caa1 · DOI
  61. Westwood, 2016, Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly, J. Alzheimers Dis., 52, 561, 10.3233/JAD-151155 · DOI
  62. Winblad, 2016, Defeating Alzheimer's disease and other dementias: a priority for European science and society, Lancet Neurol., 15, 455, 10.1016/S1474-4422(16)00062-4 · DOI · Paper page
  63. Winston, 2016, Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile, Alzheimers Dement., 3, 63, 10.1016/j.dadm.2016.04.001 · DOI · Paper page
  64. Yin, 2009, Role of soluble CD14 in cerebrospinal fluid as a regulator of glial functions, J. Neurosci. Res., 87, 2578, 10.1002/jnr.22081 · DOI
  65. Zetterberg, 2015, Plasma amyloid beta-quo vadis?, Neurobiol. Aging, 36, 2671, 10.1016/j.neurobiolaging.2015.07.021 · DOI
  66. Zetterberg, 2013, Plasma tau levels in Alzheimer's disease, Alzheimers Res. Ther., 5, 9, 10.1186/alzrt163 · DOI · Paper page

Cited by

See all 230

Metadata

Authors
Lashley, T., Schott, J. M., Weston, P., Murray, C. E., Wellington, H., Keshavan, A., Foti, S. C., Foiani, M., Toombs, J., Rohrer, J. D., Heslegrave, A., & Zetterberg, H.
Venue
Disease Models & Mechanisms
Published
2018-05-01
Volume
11
Issue
5
ISSN
  • 1754-8403 (ISSN-L)
  • 1754-8411
OpenAlex
W2799819209
Cited by
230
References
52
FWCI
19.45
Type
journal article
Language
en
Open access
gold
Funders
  • Vetenskapsrådet
  • Medical Research Council (MR/M008525/1)
  • European Research Council
  • Knut och Alice Wallenbergs Stiftelse
  • Alzheimer's Research Trust
  • Alzheimer's Association
  • Swedish State Support for Clinical Research
  • Wellcome Trust
  • Leonard Wolfson Experimental Neurology Centre (MR/M008525/1)
  • National Institute for Health Research (BRC149/NS/MH)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.